OLIG2 Immunolabeling of Mesenchymal Chondrosarcoma: Report of 14 Cases. Issue 9 (8th August 2020)

• Record Type: Journal Article
• Authors: Yao, Kun; Duan, Zejun; Yang, Shaomin; Du, Zunguo; Wang, Yin; Qi, Xueling
• Is Part Of: Journal of neuropathology and experimental neurology. Volume 79:Issue 9(2020)
• Page Start: 959
• Page End: 965
• Publication Date: 2020-08-08
• Subjects: Immunohistochemistry -- Mesenchymal chondrosarcoma -- NCOA2 rearrangement -- OLIG2; Neurology -- Diseases -- Periodicals; Neurology -- Diseases -- Physiopathology -- Periodicals; 616.8047
• DOI: 10.1093/jnen/nlaa079
• Languages: English
• ISSNs: 0022-3069

Abstract

Abstract: Mesenchymal chondrosarcoma (MC) is a rare aggressive mesenchymal sarcoma. Specific markers for the differential diagnosis of MCs remain to be developed. OLIG2 expression has been reported only in neuroepithelial tumors. Recently, OLIG2 expression was found to be involved in the development of NCOA2 fusion-positive alveolar rhabdomyosarcomas. Therefore, we investigated whether OLIG2 expression could be used as a diagnostic marker for MC. We report the clinical pathological and immunohistochemical features of 14 MCs. All tumors showed typical pathological features including biphasic patterns with sheets of primitive round mesenchymal cells and interspersed islands of cartilage. These tumors expressed BCL2, SOX9, and CD99. OLIG2 was robustly expressed in 12/14 of MCs. NCOA2 rearrangement was found in 12 cases. OLIG2 expression was not found in the NCOA2 rearrangement-negative MCs. Notably, OLIG2 expression was not detected in 52 neoplasms (8 Ewing sarcomas, 23 hemangiopericytomas, and 21 chondrosarcomas) that are frequently misdiagnosed as MC. Our findings provide convincing evidence that OLIG2 can serve as a reliable marker in the differential diagnosis of MC and may be a unique neurodevelopmental gene expression signature for the NCOA2 rearranged MCs.